LIXT
vs
S&P 500
LIXT
S&P 500
Over the past 12 months, LIXT has significantly outperformed S&P 500, delivering a return of +137% compared to the S&P 500's +33% growth.
Stocks Performance
LIXT vs S&P 500
Performance Gap
LIXT vs S&P 500
Performance By Year
LIXT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lixte Biotechnology Holdings Inc
Glance View
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
